Evidence map›Paper›PMID 33138721›Full record

ReviewThe veterinary quarterly2020

Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats.

Aaron M Izes, Jane Yu, Jacqueline M Norris, Merran Govendir

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The veterinary quarterly, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. The use of high-resolution melting analysis to distinguish feline enteric and feline infectious peritonitis coronaviruses.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. MakingAnimals : an open access journal from MDPI · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. First study onVeterinary world · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Aaron M IzesSydney School of Veterinary Science, The University of Sydney, Sydney, NSW, Australia.
Jane YuSydney School of Veterinary Science, The University of Sydney, Sydney, NSW, Australia.
Jacqueline M NorrisSydney School of Veterinary Science, The University of Sydney, Sydney, NSW, Australia.
Merran GovendirSydney School of Veterinary Science, The University of Sydney, Sydney, NSW, Australia.
University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Feline infectious peritonitis (FIP) is a viral-induced, immune-mediated disease of cats caused by virulent biotypes of feline coronaviruses (FCoV), known as the feline infectious peritonitis virus (FIPV). Historically, three major pharmacological approaches have been employed to treat FIP: (1) immunomodulators to stimulate the patient's immune system non-specifically to reduce the clinical effects of the virus through a robust immune response, (2) immunosuppressive agents to dampen clinical signs temporarily, and (3) re-purposed human antiviral drugs, all of which have been unsuccessful to date in providing reliable efficacious treatment options for FIPV. Recently, antiviral studies investigating the broad-spectrum coronavirus protease inhibitor, GC376, and the adenosine nucleoside analogue GS-441524, have resulted in increased survival rates and clinical cure in many patients. However, prescriber access to these antiviral therapies is currently problematic as they have not yet obtained registration for veterinary use. Consequently, FIP remains challenging to treat. The purpose of this review is to provide an update on the current status of therapeutics for FIP. Additionally, due to interest in coronaviruses resulting from the current human pandemic, this review provides information on domesticated cats identified as SARS-CoV-2 positive.

Indexed as

BetacoronavirusAnimalsAntiviral AgentsCatsCoronavirus InfectionsCOVID-19Feline Infectious PeritonitisImmunologic FactorsPandemicsPneumonia, ViralSARS-CoV-2Antiviral AgentsImmunologic FactorsCatfelinefeline infectious peritonitisfeline infectious peritonitis virusFIPSARS-CoV-2therapeuticstreatment

Identifiers

PMID33138721
PMCPMC7671703
OpenAlexW3097383084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.